Comparison of Pain Outcomes Between Two Anti-GD2 Antibodies in Patients With Neuroblastoma

被引:50
作者
Anghelescu, Doralina L. [1 ]
Goldberg, Jacob L. [1 ]
Faughnan, Lane G. [1 ]
Wu, Jianrong [1 ]
Mao, Shenghua [1 ]
Furman, Wayne L. [1 ]
Santana, Victor M. [1 ]
Navid, Fariba [1 ]
机构
[1] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
基金
美国国家卫生研究院;
关键词
anti-GD2; antibodies; neuroblastoma; opioids; pain; pediatric oncology; PHASE-I TRIAL; ANTIGANGLIOSIDE GD2 ANTIBODY; COLONY-STIMULATING FACTOR; MONOCLONAL-ANTIBODY; GANGLIOSIDE GD2; CLINICAL-TRIAL; CHILDREN; CH14.18; TRANSPLANTATION; INTERLEUKIN-2;
D O I
10.1002/pbc.25280
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Addition of anti-GD2 antibody ch14.18 to the treatment of neuroblastoma has improved outcomes. The most common side effect of ch14.18 is neuropathic pain, which may in part be complement-mediated. Hu14.18K322A is a humanized anti-GD2 antibody designed to diminish complement activation and induce less pain. We compare the pain outcomes in patients treated with ch14.18 and those treated with hu14.18K322A, and explore dose-dependent relationships between pain scores, opioid requirements, and complement levels in patients treated with hu14.18K322A. Procedure. Opioid (morphine equivalent mg/kg) and anxiolytic requirements during course 1 (4 days) in patients treated with hu14.18K322A and ch14.18 were reviewed. Correlations between antibody dose and pain scores, opioid requirements, and complement levels were examined for patients receiving hu14.18K322A. Results. Patients treated with hu14.18K322A (n = 19) had lower opioid requirements than those who received ch14.18 (n = 9). The differences in median opioid requirements (mg/kg) were statistically significant for the overall course (1.57 vs. 2.41, P = 0.019) as well as for Days 3 (0.34 vs. 0.65, P = 0.005), and 4 (0.32 vs. 0.64, P = 0.010). No difference in anxiolytic use was observed between the two groups. In the group treated with hu14.18K322A, we found a positive correlation between antibody dose administered and pain scores, but no correlation between antibody dose and opioid requirements or changes in complement levels. Conclusions. In this retrospective analysis, hu14.18K322A induced less pain than ch14.18 based on opioid requirements. (C) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:224 / 228
页数:5
相关论文
共 33 条
[1]  
BARKER E, 1991, CANCER RES, V51, P144
[2]  
Cheung NKV, 1998, INT J ONCOL, V12, P1299
[3]   GANGLIOSIDE GD2 SPECIFIC MONOCLONAL ANTIBODY-3F8 - A PHASE-I STUDY IN PATIENTS WITH NEUROBLASTOMA AND MALIGNANT-MELANOMA [J].
CHEUNG, NKV ;
LAZARUS, H ;
MIRALDI, FD ;
ABRAMOWSKY, CR ;
KALLICK, S ;
SAARINEN, UM ;
SPITZER, T ;
STRANDJORD, SE ;
COCCIA, PF ;
BERGER, NA .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) :1430-1440
[4]   The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report [J].
Cohn, Susan L. ;
Pearson, Andrew D. J. ;
London, Wendy B. ;
Monclair, Tom ;
Ambros, Peter F. ;
Brodeur, Garrett M. ;
Faldum, Andreas ;
Hero, Barbara ;
Iehara, Tomoko ;
Machin, David ;
Mosseri, Veronique ;
Simon, Thorsten ;
Garaventa, Alberto ;
Castel, Victoria ;
Matthay, Katherine K. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) :289-297
[5]   Advances in clinical research methodology for pain clinical trials [J].
Farrar, John T. .
NATURE MEDICINE, 2010, 16 (11) :1284-1293
[6]   Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group [J].
Gilman, Andrew L. ;
Ozkaynak, M. Fevzi ;
Matthay, Katherine K. ;
Krailo, Mark ;
Yu, Alice L. ;
Gan, Jacek ;
Sternberg, Adam ;
Hank, Jacquelyn A. ;
Seeger, Robert ;
Reaman, Gregory H. ;
Sondel, Paul M. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (01) :85-91
[7]   A PHASE-I STUDY OF NEUROBLASTOMA WITH THE ANTIGANGLIOSIDE GD2 ANTIBODY 14.G2A [J].
HANDGRETINGER, R ;
BAADER, P ;
DOPFER, R ;
KLINGEBIEL, T ;
REULAND, P ;
TREUNER, J ;
REISFELD, RA ;
NIETHAMMER, D .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1992, 35 (03) :199-204
[8]   A PHASE-I STUDY OF HUMAN MOUSE CHIMERIC ANTIGANGLIOSIDE GD2 ANTIBODY CH14.18 IN PATIENTS WITH NEUROBLASTOMA [J].
HANDGRETINGER, R ;
ANDERSON, K ;
LANG, P ;
DOPFER, R ;
KLINGEBIEL, T ;
SCHRAPPE, M ;
REULAND, P ;
GILLIES, SD ;
REISFELD, RA ;
NIETHAMMER, D .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (02) :261-267
[9]  
Hockenberry M.J., 2009, Wong's essentials of pediatric nursing, V8th
[10]   Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. [J].
Imai, M ;
Landen, C ;
Ohta, R ;
Cheung, NKV ;
Tomlinson, S .
CANCER RESEARCH, 2005, 65 (22) :10562-10568